Literature DB >> 3144536

In-vitro activity of fleroxacin compared with three other quinolones.

D A Bremner1, A S Dickie, K P Singh.   

Abstract

The in-vitro activity of fleroxacin (Ro23-6240), a new synthetic quinolone, was compared with that of three other quinolones against 665 clinical isolates of aerobic bacteria by the agar dilution technique. Fleroxacin showed similar activity to norfloxacin, enoxacin and pefloxacin against most isolates of Enterobacteriaceae, Neisseria meningitidis, N. gonorrhoeae, Haemophilis influenzae, Staphylococcus spp. and streptococcus faecalis. Fleroxacin was the most active quinolone against Enterobacter spp. Fleroxacin was not as active against Pseudomonas aeruginosa, but the MIC90 (4 mg/l) is still below the reported peak serum level after a standard oral dose of 400 mg.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3144536     DOI: 10.1093/jac/22.supplement_d.19

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  10 in total

1.  Pharmacokinetics and serum bactericidal activities of quinolones in combination with clindamycin, metronidazole, and ornidazole.

Authors:  M Boeckh; H Lode; K M Deppermann; S Grineisen; F Shokry; R Held; K Wernicke; P Koeppe; J Wagner; C Krasemann
Journal:  Antimicrob Agents Chemother       Date:  1990-12       Impact factor: 5.191

2.  Disposition of fleroxacin, a new trifluoroquinolone, and its metabolites. Pharmacokinetics in renal failure and influence of haemodialysis.

Authors:  E Singlas; A Leroy; E Sultan; M Godin; B Moulin; A M Taburet; M Dhib; J P Fillastre
Journal:  Clin Pharmacokinet       Date:  1990-07       Impact factor: 6.447

Review 3.  Fleroxacin clinical pharmacokinetics.

Authors:  A E Stuck; D K Kim; F J Frey
Journal:  Clin Pharmacokinet       Date:  1992-02       Impact factor: 6.447

4.  Comparative in vitro activity of a new quinolone, fleroxacin, against respiratory pathogens from patients with cystic fibrosis.

Authors:  J C Akaniro; C E Vidaurre; H R Stutman; M I Marks
Journal:  Antimicrob Agents Chemother       Date:  1990-10       Impact factor: 5.191

5.  Fleroxacin pharmacokinetics in patients with liver cirrhosis.

Authors:  R A Blouin; B A Hamelin; D A Smith; T S Foster; W J John; H A Welker
Journal:  Antimicrob Agents Chemother       Date:  1992-03       Impact factor: 5.191

6.  Characterization of peripheral-compartment kinetics of antibiotics by in vivo microdialysis in humans.

Authors:  M Müller; O Haag; T Burgdorff; A Georgopoulos; W Weninger; B Jansen; G Stanek; H Pehamberger; E Agneter; H G Eichler
Journal:  Antimicrob Agents Chemother       Date:  1996-12       Impact factor: 5.191

7.  Pharmacokinetics of [18F]fleroxacin in patients with acute exacerbations of chronic bronchitis and complicated urinary tract infection studied by positron emission tomography.

Authors:  A J Fischman; E Livni; J W Babich; N M Alpert; A Bonab; S Chodosh; F McGovern; P Kamitsuka; Y Y Liu; R Cleeland; B L Prosser; J A Correia; R H Rubin
Journal:  Antimicrob Agents Chemother       Date:  1996-03       Impact factor: 5.191

8.  Penetration of ciprofloxacin and fleroxacin into biliary tract.

Authors:  C E Edmiston; E C Suarez; A P Walker; M P Demeure; C T Frantzides; W J Schulte; S D Wilson
Journal:  Antimicrob Agents Chemother       Date:  1996-03       Impact factor: 5.191

9.  Pharmacokinetics of [18F]fleroxacin in healthy human subjects studied by using positron emission tomography.

Authors:  A J Fischman; E Livni; J Babich; N M Alpert; Y Y Liu; E Thom; R Cleeland; B L Prosser; J A Correia; H W Strauss
Journal:  Antimicrob Agents Chemother       Date:  1993-10       Impact factor: 5.191

Review 10.  Fleroxacin. A review of its pharmacology and therapeutic efficacy in various infections.

Authors:  J A Balfour; P A Todd; D H Peters
Journal:  Drugs       Date:  1995-05       Impact factor: 9.546

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.